SCHEMBL2412207

SCHEMBL2412207

CC(C)(Sc1nc(CCOc2ccc(-c3cccc(OC(F)(F)F)c3)cc2)cs1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 1/20 0.42
CTSA P10619 4/20 0.40
FFAR4 Q5NUL3 3/20 0.40
FFAR1 O14842 2/20 0.40
PPARA Q07869 4/20 0.40
PPARG P37231 3/20 0.40
DHODH Q02127 1/20 0.39
LDHA P00338 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
STK17B O94768 1/20 0.38
TP53 P04637 1/20 0.37
PIM1 P11309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2410233 0.92 SHMT2 (0.42) PPARAPPARGHDAC1HDAC2
SCHEMBL2410198 0.90 PIM1 (0.42) SLC13A5CTSAFFAR4FFAR1DHODH
SCHEMBL2412948 0.89 PPARA (0.42) SLC13A5FFAR1PPARAPPARG
SCHEMBL2408505 0.89 TP53 (0.45) FFAR1PPARAPPARGTP53
SCHEMBL2410667 0.89 MRGPRX4 (0.41) SLC13A5FFAR4FFAR1PPARAHDAC1
SCHEMBL2414869 0.89 PPARA (0.41) PPARAPPARG
SCHEMBL2415153 0.88 PPARA (0.45) PPARAPPARG
SCHEMBL2398837 0.85 RAB9A (0.49) FFAR1PPARAPPARGTP53
SCHEMBL2413963 0.84 PPARA (0.45) FFAR1PPARAPPARGTP53
SCHEMBL2412787 0.84 SHMT2 (0.39) PPARAPPARGHDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG SLC13A5 1838/4885CTSA 2272/4885FFAR4 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.